Sep 12, 2022 / 07:30PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co. - Managing Director, Senior Healthcare Analyst
Good afternoon and thanks for joining us to have a conversation with Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that employ health and offer hope for patients across the globe.
The company's lead program in gene therapies, OCU400, is currently in the clinic. Additionally, the company has also entered into a development and commercial agreement with an Indian pharma, Bharat Biotech, to commercialize their whole-variant inactivated COVID-19 vaccine called Covaxin.
Covaxin currently has been approved under an EUA in India. The company has regulatory applications for marketing Covaxin in the US, Canada, and Mexico. Additionally, Ocugen recently initiated a clinical program with NeoCart that currently has RMAT designation. So to learn about the deep pipeline of Ocugen, let's get started with Shankar.
Shankar, glad to see you, and I
Ocugen Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers